NYSE:ABT - Abbott Laboratories Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$61.48 -0.63 (-1.01 %)
(As of 05/22/2018 01:37 PM ET)
Previous Close$61.97
Today's Range$60.97 - $62.29
52-Week Range$43.10 - $64.60
Volume336,853 shs
Average Volume5.61 million shs
Market Capitalization$108.19 billion
P/E Ratio24.69
Dividend Yield1.81%
Beta1.5

About Abbott Laboratories (NYSE:ABT)

Abbott Laboratories logoAbbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; benchtop systems and rapid tests in the areas of infectious diseases; molecular point-of-care test systems for influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

Receive ABT News and Ratings via Email

Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:ABT
CUSIP00282410
Phone224-667-6100

Debt

Debt-to-Equity Ratio0.67
Current Ratio1.66
Quick Ratio1.24

Price-To-Earnings

Trailing P/E Ratio24.69
Forward P/E Ratio21.50
P/E Growth1.77

Sales & Book Value

Annual Sales$27.39 billion
Price / Sales3.94
Cash Flow$4.7696 per share
Price / Cash12.89
Book Value$17.87 per share
Price / Book3.44

Profitability

EPS (Most Recent Fiscal Year)$2.50
Net Income$477 million
Net Margins1.67%
Return on Equity14.54%
Return on Assets6.34%

Miscellaneous

Employees99,000
Outstanding Shares1,753,190,000

Abbott Laboratories (NYSE:ABT) Frequently Asked Questions

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories declared a quarterly dividend on Friday, February 16th. Shareholders of record on Friday, April 13th will be paid a dividend of $0.28 per share on Tuesday, May 15th. This represents a $1.12 dividend on an annualized basis and a yield of 1.82%. The ex-dividend date is Thursday, April 12th. View Abbott Laboratories' Dividend History.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) announced its earnings results on Wednesday, April, 18th. The healthcare product maker reported $0.59 EPS for the quarter, topping the Zacks' consensus estimate of $0.58 by $0.01. The healthcare product maker earned $7.39 billion during the quarter, compared to analyst estimates of $7.28 billion. Abbott Laboratories had a return on equity of 14.54% and a net margin of 1.67%. Abbott Laboratories's revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the company posted $0.48 earnings per share. View Abbott Laboratories' Earnings History.

When is Abbott Laboratories' next earnings date?

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, July, 19th 2018. View Earnings Estimates for Abbott Laboratories.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories issued an update on its FY18 earnings guidance on Wednesday, April, 18th. The company provided EPS guidance of $2.80-2.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.86. Abbott Laboratories also updated its Q2 guidance to $0.70-0.72 EPS.

What price target have analysts set for ABT?

17 analysts have issued 12-month target prices for Abbott Laboratories' shares. Their forecasts range from $56.00 to $80.00. On average, they anticipate Abbott Laboratories' share price to reach $68.4375 in the next twelve months. View Analyst Ratings for Abbott Laboratories.

Are investors shorting Abbott Laboratories?

Abbott Laboratories saw a increase in short interest during the month of April. As of April 30th, there was short interest totalling 14,602,527 shares, an increase of 52.8% from the April 13th total of 9,557,285 shares. Based on an average daily volume of 6,737,663 shares, the days-to-cover ratio is presently 2.2 days. Currently, 0.8% of the shares of the stock are short sold.

Who are some of Abbott Laboratories' key competitors?

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the folowing people:
  • Mr. Miles D. White, Chairman & CEO (Age 63)
  • Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 48)
  • Mr. Brian J. Blaser, Exec. VP of Diagnostic Products (Age 53)
  • Scott M. Leinenweber, VP of Investor Relations
  • Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 52)

Has Abbott Laboratories been receiving favorable news coverage?

News articles about ABT stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Abbott Laboratories earned a media sentiment score of 0.15 on Accern's scale. They also gave news articles about the healthcare product maker an impact score of 47.36 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Abbott Laboratories' major shareholders?

Abbott Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.39%), Massachusetts Financial Services Co. MA (2.28%), Northern Trust Corp (1.49%), Diamond Hill Capital Management Inc. (0.60%), FIL Ltd (0.54%) and Dimensional Fund Advisors LP (0.54%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

Which major investors are selling Abbott Laboratories stock?

ABT stock was sold by a variety of institutional investors in the last quarter, including Independent Franchise Partners LLP, Massachusetts Financial Services Co. MA, Flossbach Von Storch AG, Coho Partners Ltd., Swiss National Bank, American Century Companies Inc., Northern Trust Corp and Legal & General Group Plc. Company insiders that have sold Abbott Laboratories company stock in the last year include Alejandro D Wellisch, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, Miles D White, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

Which major investors are buying Abbott Laboratories stock?

ABT stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Montag & Caldwell LLC, Ceredex Value Advisors LLC, Eaton Vance Management, Summit Trail Advisors LLC, Mackay Shields LLC, CIBC World Markets Inc. and Franklin Resources Inc.. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Daniel J Starks, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.

How do I buy shares of Abbott Laboratories?

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of ABT stock can currently be purchased for approximately $61.53.

How big of a company is Abbott Laboratories?

Abbott Laboratories has a market capitalization of $108.19 billion and generates $27.39 billion in revenue each year. The healthcare product maker earns $477 million in net income (profit) each year or $2.50 on an earnings per share basis. Abbott Laboratories employs 99,000 workers across the globe.

How can I contact Abbott Laboratories?

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.


MarketBeat Community Rating for Abbott Laboratories (ABT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  641 (Vote Outperform)
Underperform Votes:  492 (Vote Underperform)
Total Votes:  1,133
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Abbott Laboratories (NYSE:ABT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
17 Wall Street analysts have issued ratings and price targets for Abbott Laboratories in the last 12 months. Their average twelve-month price target is $68.4375, suggesting that the stock has a possible upside of 11.32%. The high price target for ABT is $80.00 and the low price target for ABT is $56.00. There are currently 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.822.782.742.60
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $68.4375$67.00$65.5556$56.5333
Price Target Upside: 11.32% upside13.19% upside4.30% upside1.37% upside

Abbott Laboratories (NYSE:ABT) Consensus Price Target History

Price Target History for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/24/2018CitigroupLower Price TargetNeutral ➝ Neutral$66.00 ➝ $65.00LowView Rating Details
4/22/2018BTIG ResearchReiterated RatingHoldLowView Rating Details
1/30/2018ArgusBoost Price TargetBuy$66.00 ➝ $80.00LowView Rating Details
1/25/2018BarclaysBoost Price TargetOverweight ➝ Overweight$66.00 ➝ $70.00LowView Rating Details
1/25/2018GuggenheimReiterated RatingBuy$72.00LowView Rating Details
1/25/2018Royal Bank of CanadaReiterated RatingBuy$67.00LowView Rating Details
1/25/2018Leerink SwannReiterated RatingMarket Perform$60.00 ➝ $68.00LowView Rating Details
1/25/2018JPMorgan ChaseBoost Price TargetOverweight ➝ Overweight$65.00 ➝ $69.00HighView Rating Details
1/25/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$67.00 ➝ $70.00HighView Rating Details
1/25/2018Wells FargoBoost Price TargetOutperform$66.00 ➝ $70.00MediumView Rating Details
1/25/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$65.00 ➝ $70.00MediumView Rating Details
1/25/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$63.00 ➝ $71.00MediumView Rating Details
1/25/2018William BlairUpgradeMarket Perform ➝ OutperformMediumView Rating Details
1/24/2018Bank of AmericaBoost Price Target$60.00 ➝ $70.00HighView Rating Details
1/3/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$64.00LowView Rating Details
10/19/2017CowenSet Price TargetBuy$55.00 ➝ $68.00N/AView Rating Details
10/19/2017Jefferies GroupReiterated RatingBuy$65.00N/AView Rating Details
5/16/2017Goldman SachsInitiated CoverageNeutral ➝ Neutral$45.00LowView Rating Details
4/18/2017UBSReiterated RatingNeutral$41.00N/AView Rating Details
8/9/2016Deutsche BankReiterated RatingBuyN/AView Rating Details
6/21/2016Edward JonesUpgradeHold ➝ BuyN/AView Rating Details
6/8/2016Credit Suisse GroupReiterated RatingBuyN/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Abbott Laboratories (NYSE:ABT) Earnings History and Estimates Chart

Earnings by Quarter for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) Earnings Estimates

2018 EPS Consensus Estimate: $2.83
2019 EPS Consensus Estimate: $3.20
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.57$0.58$0.57
Q2 20183$0.71$0.71$0.71
Q3 20183$0.73$0.75$0.74
Q4 20183$0.79$0.83$0.81
Q1 20192$0.66$0.66$0.66
Q2 20192$0.79$0.79$0.79
Q3 20192$0.82$0.82$0.82
Q4 20192$0.92$0.93$0.93

Abbott Laboratories (NYSE ABT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/18/2018$0.71N/AView Earnings Details
4/18/2018Q1 18$0.58$0.59$7.2831 billion$7.39 billionViewN/AView Earnings Details
1/24/2018Q4 2017$0.73$0.74$7.3844 billion$7.5890 billionViewListenView Earnings Details
10/18/20179/30/2017$0.65$0.66$6.7160 billion$6.8290 billionViewN/AView Earnings Details
7/20/2017Q2 2017$0.60$0.62$6.6273 billion$6.6370 billionViewN/AView Earnings Details
4/19/20173/31/2017$0.43$0.48$6.1623 billion$6.3350 billionViewN/AView Earnings Details
1/25/2017Q416$0.64$0.65$5.41 billion$5.33 billionViewListenView Earnings Details
10/19/2016Q316$0.58$0.59$5.29 billion$5.30 billionViewListenView Earnings Details
7/20/2016Q216$0.53$0.55$5.24 billion$5.30 billionViewListenView Earnings Details
4/20/2016Q116$0.39$0.41$4.77 billion$4.90 billionViewListenView Earnings Details
1/28/2016Q415$0.61$0.62$5.31 billion$5.20 billionViewListenView Earnings Details
10/21/2015Q315$0.53$0.54$5.16 billion$5.15 billionViewListenView Earnings Details
7/22/2015Q215$0.50$0.52$5.15 billion$5.20 billionViewListenView Earnings Details
4/22/2015Q115$0.42$0.47$4.85 billion$4.90 billionViewListenView Earnings Details
1/29/2015Q414$0.68$0.71$5.48 billion$5.36 billionViewListenView Earnings Details
10/22/2014Q314$0.60$0.62$5.62 billion$5.10 billionViewListenView Earnings Details
7/16/2014Q214$0.51$0.54$5.53 billion$5.55 billionViewListenView Earnings Details
4/16/2014Q114$0.36$0.41$5.29 billion$5.24 billionViewListenView Earnings Details
1/22/2014Q413$0.58$0.58$5.72 billion$5.66 billionViewListenView Earnings Details
10/16/2013Q313$0.52$0.55$5.46 billion$5.37 billionViewListenView Earnings Details
7/17/2013Q2 2013$0.44$0.46$5.53 billion$5.45 billionViewListenView Earnings Details
4/17/2013Q1 2013$0.41$0.42$5.42 billion$5.38 billionViewListenView Earnings Details
1/23/2013Q4 2012$1.50$1.51$10.58 billion$10.80 billionViewListenView Earnings Details
10/17/2012$1.28$1.30ViewN/AView Earnings Details
7/18/2012$1.22$1.23ViewN/AView Earnings Details
4/18/2012$1.00$1.03ViewN/AView Earnings Details
1/25/2012$1.44$1.45ViewN/AView Earnings Details
10/19/2011$1.17$1.18ViewN/AView Earnings Details
7/20/2011$1.12$1.12ViewN/AView Earnings Details
4/20/2011$0.90$0.91ViewN/AView Earnings Details
1/26/2011$1.29$1.30ViewN/AView Earnings Details
10/20/2010Q3 2010$1.04$1.05ViewN/AView Earnings Details
7/21/2010Q2 2010$1.00$1.01ViewN/AView Earnings Details
4/21/2010Q1 2010$0.80$0.81ViewN/AView Earnings Details
1/27/2010Q4 2009$1.17$1.18ViewN/AView Earnings Details
10/14/2009Q3 2009$0.90$0.92ViewN/AView Earnings Details
7/15/2009Q2 2009$0.89$0.90ViewN/AView Earnings Details
4/15/2009Q1 2009$0.70$0.73ViewN/AView Earnings Details
1/21/2009Q4 2008$1.06$1.06ViewN/AView Earnings Details
10/15/2008Q3 2008$0.77$0.79ViewN/AView Earnings Details
7/16/2008Q2 2008$0.78$0.84ViewN/AView Earnings Details
4/16/2008Q1 2008$0.63$0.63ViewN/AView Earnings Details
1/23/2008Q4 2007$0.92$0.93ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Abbott Laboratories (NYSE:ABT) Dividend Information

Abbott Laboratories pays an annual dividend of $1.12 per share, with a dividend yield of 1.82%. ABT's most recent quarterly dividend payment was Tuesday, May 15. The company has grown its dividend for the last 45 consecutive years and is increasing its dividend by an average of 6.40% each year. Abbott Laboratories pays out 44.80% of its earnings out as a dividend.
Most Recent Dividend:5/15/2018
Annual Dividend:$1.12
Dividend Yield:1.82%
Dividend Growth:6.40% (3 Year Average)
Payout Ratio(s):44.80% (Trailing 12 Months of Earnings)
39.16% (Based on This Year's Estimates)
34.78% (Based on Next Year's Estimates)
23.48% (Based on Cash Flow)
Track Record:45 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/16/2018quarterly$0.281.85415114642828%4/12/20184/13/20185/15/2018
12/15/2017quarterly$0.281.99%1/11/20181/12/20182/15/2018
9/15/2017quarterly$0.26502.05%10/12/201710/13/201711/15/2017
6/9/2017quarterly$0.26502.25%7/12/20177/14/20178/15/2017
2/17/2017quarterly$0.26502.36%4/11/20174/14/20175/15/2017
12/9/2016quarterly$0.26502.7%1/11/20171/13/20172/15/2017
9/15/2016quarterly$0.262.48%10/12/201610/14/201611/15/2016
6/10/2016quarterly$0.262.75%7/13/20167/15/20168/15/2016
2/19/2016quarterly$0.262.66%4/13/20164/15/20165/16/2016
12/11/2015quarterly$0.262.32%1/13/20161/15/20162/16/2016
9/17/2015quarterly$0.242.22%10/13/201510/15/201511/15/2015
6/12/2015quarterly$0.242%7/13/20157/15/20158/15/2015
2/20/2015quarterly$0.242.03%4/13/20154/15/20155/15/2015
12/12/2014quarterly$0.242.21%1/13/20151/15/20152/13/2015
9/11/2014quarterly$0.222.07%10/10/201410/15/201411/15/2014
6/13/2014quarterly$0.222.21%7/11/20147/15/20148/15/2014
2/21/2014quarterly$0.222.26%4/11/20144/15/20145/15/2014
10/16/2013quarterly$0.222.37%1/13/20141/15/20142/15/2014
9/12/2013quarterly$0.141.61%10/10/201310/15/201311/15/2013
6/14/2013quarterly$0.141.52%7/11/20137/15/20138/15/2013
2/15/2013quarterly$0.141.61%4/11/20134/15/20135/15/2013
12/14/2012quarterly$0.140.86%1/11/20131/15/20132/15/2013
(Data available from 1/1/2013 forward)

Insider Trades

Abbott Laboratories (NYSE ABT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.74%
Institutional Ownership Percentage: 72.09%
Insider Trading History for Abbott Laboratories (NYSE:ABT)
Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE ABT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/18/2018Daniel Gesua Sive SalvadoriInsiderSell3,000$61.20$183,600.0095,581View SEC Filing  
5/4/2018Sharon J BrackenSVPSell2,150$58.56$125,904.0043,990View SEC Filing  
4/23/2018Jaime ContrerasInsiderSell849$59.36$50,396.6450,436View SEC Filing  
3/9/2018Roger BirdInsiderSell8,262$62.75$518,440.5058,574View SEC Filing  
3/7/2018Jared WatkinInsiderSell3,000$61.19$183,570.0068,215View SEC Filing  
3/5/2018Sharon J BrackenSVPSell2,100$60.27$126,567.0044,790View SEC Filing  
3/1/2018Jared WatkinSVPSell996$58.87$58,634.5269,511View SEC Filing  
3/1/2018Sharon J BrackenInsiderSell1,053$58.93$62,053.29View SEC Filing  
3/1/2018Stephen R FussellEVPSell11,106$60.13$667,803.78172,158View SEC Filing  
2/27/2018Daniel J StarksDirectorBuy40,037$60.67$2,429,044.796,943,348View SEC Filing  
2/20/2018Jared WatkinSVPSell297$59.29$17,609.1374,357View SEC Filing  
2/20/2018Stephen R FussellInsiderSell56,401$59.61$3,362,063.61184,884View SEC Filing  
1/31/2018Brian J BlaserInsiderSell27,733$62.26$1,726,656.58156,587View SEC Filing  
1/30/2018Stephen R FussellEVPSell13,313$62.84$836,588.92152,343View SEC Filing  
12/14/2017Daniel Gesua Sive SalvadoriInsiderSell28,319$54.92$1,555,279.48102,117View SEC Filing  
12/6/2017Miles D WhiteChairmanSell276,886$54.41$15,065,367.263,677,913View SEC Filing  
11/30/2017Sharon J BrackenInsiderSell2,188$56.12$122,790.5625,618View SEC Filing  
11/22/2017Alejandro D WellischInsiderSell2,153$55.86$120,266.5810,256View SEC Filing  
11/17/2017Brian J BlaserInsiderSell23,866$55.55$1,325,756.30146,387View SEC Filing  
11/14/2017Daniel Gesua Sive SalvadoriInsiderSell71,157$55.00$3,913,635.00144,955View SEC Filing  
10/23/2017Daniel Gesua Sive SalvadoriEVPSell96,603$56.21$5,430,054.63142,082View SEC Filing  
9/26/2017Daniel Gesua Sive SalvadoriInsiderSell62,460$52.95$3,307,257.00113,426View SEC Filing  
9/22/2017Jaime ContrerasInsiderSell52,700$51.97$2,738,819.0058,739View SEC Filing  
8/16/2017Stephen R FussellInsiderSell196,550$49.50$9,729,225.00221,488View SEC Filing  
8/1/2017Sharon J BrackenInsiderSell2,000$49.16$98,320.0028,806View SEC Filing  
7/27/2017Brian J BlaserInsiderSell15,000$50.00$750,000.00143,154View SEC Filing  
7/25/2017Hubert L AllenInsiderSell4,600$50.79$233,634.00105,479View SEC Filing  
6/15/2017Jared WatkinInsiderSell552$47.97$26,479.4447,090View SEC Filing  
6/8/2017Stephen R FussellInsiderSell196,550$46.00$9,041,300.00221,488View SEC Filing  
4/27/2017Roger BirdInsiderSell5,600$43.82$245,392.0051,313View SEC Filing  
4/26/2017Joseph J ManningInsiderSell4,200$43.95$184,590.0026,224View SEC Filing  
3/1/2017Michael J. WarmuthInsiderSell3,851$45.39$174,796.89View SEC Filing  
2/23/2017Robert E FunckVPSell25,500$45.50$1,160,250.00117,579View SEC Filing  
2/22/2017Roger BirdInsiderSell13,222$45.02$595,254.4463,910View SEC Filing  
2/21/2017Deepak S NathInsiderSell319$44.98$14,348.6258,471View SEC Filing  
1/31/2017Heather L MasonInsiderSell35,700$40.77$1,455,489.00100,189View SEC Filing  
12/20/2016Brian J BlaserInsiderBuy15,580$38.45$599,051.00129,782View SEC Filing  
12/14/2016Robert B FordInsiderBuy12,775$39.09$499,374.7551,532View SEC Filing  
11/10/2016Miles D WhiteChairmanBuy121,456$40.45$4,912,895.202,802,558View SEC Filing  
11/1/2016Sally E BlountDirectorBuy5,100$39.24$200,124.0020,143View SEC Filing  
9/26/2016Daniel Gesua Sive SalvadoriSVPSell815$41.71$33,993.6559,791View SEC Filing  
7/28/2016Stephen R FussellInsiderSell41,500$45.00$1,867,500.00196,467View SEC Filing  
7/26/2016Michael J WarmuthInsiderSell26,800$43.49$1,165,532.0081,811View SEC Filing  
7/25/2016Miles D WhiteChairmanBuy242,547$43.18$10,473,179.462,010,517View SEC Filing  
7/25/2016Robert E FunckVPSell26,800$43.08$1,154,544.00111,819View SEC Filing  
6/28/2016Hubert L AllenEVPSell3,400$37.14$126,276.0091,857View SEC Filing  
6/15/2016Jared WatkinSVPSell552$37.63$20,771.7647,114View SEC Filing  
6/1/2016Brian B YoorCFOSell565$39.49$22,311.8550,182View SEC Filing  
4/28/2016Deepak S NathSVPSell53$41.31$2,189.4347,435View SEC Filing  
3/31/2016Jaime ContrerasSVPSell462$41.78$19,302.3647,667View SEC Filing  
2/29/2016Brian B YoorCFOSell865$39.12$33,838.8052,250View SEC Filing  
2/29/2016Deepak S NathSVPSell793$39.27$31,141.1148,364View SEC Filing  
2/29/2016Robert B FordEVPSell1,706$39.28$67,011.6862,495View SEC Filing  
2/29/2016Robert E FunckVPSell1,333$39.30$52,386.9086,352View SEC Filing  
2/22/2016Jared WatkinSVPSell554$39.09$21,655.8650,515View SEC Filing  
2/16/2016Deepak S. NathSVPSell171$37.13$6,349.2334,941View SEC Filing  
12/16/2015Miles D. WhiteCEOSell438,000$46.00$20,148,000.001,394,153View SEC Filing  
8/18/2015Stephen R. FussellEVPSell13,096$50.46$660,824.16130,601View SEC Filing  
4/27/2015Heather L MasonEVPSell13,500$47.45$640,575.00View SEC Filing  
4/27/2015Roger BirdSVPSell28,548$47.57$1,358,028.36View SEC Filing  
3/26/2015J. Scott WhiteSVPSell12,483$46.68$582,706.44View SEC Filing  
3/2/2015Jaime ContrerasSVPSell9,209$47.34$435,954.06View SEC Filing  
2/4/2015John M CapekEVPSell34,292$45.66$1,565,772.72View SEC Filing  
11/25/2014Jaime ContrerasSVPSell51,600$44.07$2,274,012.00View SEC Filing  
10/29/2014Miles D WhiteCEOSell440,800$42.52$18,742,816.00View SEC Filing  
3/3/2014John LandgrafEVPSell17,293$39.38$680,998.3495,131View SEC Filing  
3/3/2014Katherine DoyleSVPSell6,639$39.01$258,987.3947,525View SEC Filing  
3/3/2014Robert FunckVPSell1,413$38.97$55,064.6162,926View SEC Filing  
2/18/2014John LandgrafEVPSell1,583$39.10$61,895.30102,421View SEC Filing  
1/29/2014Michael WarmuthEVPSell11,430$36.21$413,880.3040,487View SEC Filing  
12/6/2013Jean-Yves PaveeSVPSell5,855$37.46$219,328.3030,901View SEC Filing  
11/7/2013Stephen FussellEVPSell10,466$37.59$393,416.94101,169View SEC Filing  
10/30/2013Jaime ContrerasSVPSell25,368$36.85$934,810.80View SEC Filing  
6/7/2013Heather L MasonSVPSell12,000$37.01$444,120.00View SEC Filing  
2/1/2013William A OsbornDirectorBuy10,000$33.86$338,600.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Abbott Laboratories (NYSE ABT) News Headlines

Source:
DateHeadline
Five-Year Study Data Confirm Positive Outcomes for Patients When Abbott Diagnostic Tool Was Used to Guide Heart Stenting DecisionsFive-Year Study Data Confirm Positive Outcomes for Patients When Abbott Diagnostic Tool Was Used to Guide Heart Stenting Decisions
finance.yahoo.com - May 22 at 8:10 AM
Abbott Laboratories (ABT) Insider Daniel Gesua Sive Salvadori Sells 3,000 SharesAbbott Laboratories (ABT) Insider Daniel Gesua Sive Salvadori Sells 3,000 Shares
www.americanbankingnews.com - May 21 at 7:52 PM
Shocking the Spine Offers an Alternative to OpioidsShocking the Spine Offers an Alternative to Opioids
finance.yahoo.com - May 21 at 8:45 AM
$0.71 Earnings Per Share Expected for Abbott Laboratories (ABT) This Quarter$0.71 Earnings Per Share Expected for Abbott Laboratories (ABT) This Quarter
www.americanbankingnews.com - May 21 at 3:26 AM
Why Is Abbott (ABT) Up 2% Since Its Last Earnings Report?Why Is Abbott (ABT) Up 2% Since Its Last Earnings Report?
finance.yahoo.com - May 18 at 5:18 PM
How Did Bausch + Lomb Perform in 1Q18?How Did Bausch + Lomb Perform in 1Q18?
finance.yahoo.com - May 15 at 5:22 PM
Will Abbott Laboratories (NYSE:ABT) Continue To Underperform Its Industry?Will Abbott Laboratories (NYSE:ABT) Continue To Underperform Its Industry?
finance.yahoo.com - May 15 at 8:38 AM
Abbott Laboratories (ABT) Sees Significant Growth in Short InterestAbbott Laboratories (ABT) Sees Significant Growth in Short Interest
www.americanbankingnews.com - May 14 at 1:33 AM
Heart Device Procedure Is No Better Than Drug Therapy for Irregular Heartbeat: StudyHeart Device Procedure Is No Better Than Drug Therapy for Irregular Heartbeat: Study
www.wsj.com - May 12 at 5:19 PM
[$$] Heart Device Procedure Is No Better Than Drug Therapy for Irregular Heartbeat: Study[$$] Heart Device Procedure Is No Better Than Drug Therapy for Irregular Heartbeat: Study
finance.yahoo.com - May 11 at 9:28 AM
Insider Selling: Abbott Laboratories (ABT) SVP Sells 2,150 Shares of StockInsider Selling: Abbott Laboratories (ABT) SVP Sells 2,150 Shares of Stock
www.americanbankingnews.com - May 8 at 8:16 PM
Is It Time To Buy Abbott Laboratories (NYSE:ABT)?Is It Time To Buy Abbott Laboratories (NYSE:ABT)?
finance.yahoo.com - May 8 at 8:40 AM
How Analysts View Allergan after Its 1Q18 EarningsHow Analysts View Allergan after Its 1Q18 Earnings
finance.yahoo.com - May 8 at 8:39 AM
How this pharma executive retired to help people around the worldHow this pharma executive retired to help people around the world
www.marketwatch.com - May 7 at 5:17 PM
Absolute Reports Fiscal 2018 Third Quarter Financial ResultsAbsolute Reports Fiscal 2018 Third Quarter Financial Results
www.businesswire.com - May 7 at 5:17 PM
A Brief Look at Abbott’s Alere Integration Progress and RecoveryA Brief Look at Abbott’s Alere Integration Progress and Recovery
finance.yahoo.com - May 7 at 5:17 PM
Abbott’s CRM Business Was Flat in 1Q18—What’s Ahead?Abbott’s CRM Business Was Flat in 1Q18—What’s Ahead?
finance.yahoo.com - May 7 at 9:26 AM
Discussing Abbott’s Market Position and Growth Prospects in ChinaDiscussing Abbott’s Market Position and Growth Prospects in China
finance.yahoo.com - May 7 at 9:26 AM
$7.76 Billion in Sales Expected for Abbott Laboratories (ABT) This Quarter$7.76 Billion in Sales Expected for Abbott Laboratories (ABT) This Quarter
www.americanbankingnews.com - May 5 at 2:50 AM
Despite Youth On Farm, Abbott Ventures Chief Avoids Spreading ManureDespite Youth On Farm, Abbott Ventures Chief Avoids Spreading Manure
finance.yahoo.com - May 4 at 5:23 PM
ABT’s Medical Devices Business: A Key Growth DriverABT’s Medical Devices Business: A Key Growth Driver
finance.yahoo.com - May 4 at 8:26 AM
$0.71 EPS Expected for Abbott Laboratories (ABT) This Quarter$0.71 EPS Expected for Abbott Laboratories (ABT) This Quarter
www.americanbankingnews.com - May 3 at 9:38 PM
Abbott Expands Cardiac Arrhythmias Portfolio with FDA Clearance of Advanced Mapping CatheterAbbott Expands Cardiac Arrhythmias Portfolio with FDA Clearance of Advanced Mapping Catheter
finance.yahoo.com - May 3 at 5:17 PM
Abbotts XIENCE Sierra™ Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery DiseaseAbbott's XIENCE Sierra™ Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery Disease
finance.yahoo.com - May 2 at 5:14 PM
June 2019 Options Now Available For Abbott Laboratories (ABT)June 2019 Options Now Available For Abbott Laboratories (ABT)
www.nasdaq.com - April 30 at 5:24 PM
Abbott Laboratories (ABT) Receives Average Rating of "Buy" from BrokeragesAbbott Laboratories (ABT) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 30 at 7:51 AM
Stocks Rally As Investors Like Facebook Results, AMD Powers ChipsStocks Rally As Investors Like Facebook Results, AMD Powers Chips
finance.yahoo.com - April 26 at 5:13 PM
Abbott Laboratories (ABT) Insider Jaime Contreras Sells 849 SharesAbbott Laboratories (ABT) Insider Jaime Contreras Sells 849 Shares
www.americanbankingnews.com - April 25 at 7:28 PM
Abbott Laboratories Registered Organic Growth of 7% in 1Q18Abbott Laboratories Registered Organic Growth of 7% in 1Q18
finance.yahoo.com - April 25 at 5:13 PM
Citigroup Trims Abbott Laboratories (ABT) Target Price to $65.00Citigroup Trims Abbott Laboratories (ABT) Target Price to $65.00
www.americanbankingnews.com - April 24 at 11:02 AM
Boston Scientific’s 1Q18 Revenues: What to ExpectBoston Scientific’s 1Q18 Revenues: What to Expect
finance.yahoo.com - April 24 at 8:32 AM
BRIEF-Abbott Laboratories - Co, Sanquin Sign Multiple-Year Contract For Supply Of Primary Serological Equipment ...BRIEF-Abbott Laboratories - Co, Sanquin Sign Multiple-Year Contract For Supply Of Primary Serological Equipment ...
www.reuters.com - April 23 at 5:03 PM
Sanquin Selects Abbotts "Alinity™ s" Solution for Blood and Plasma ScreeningSanquin Selects Abbott's "Alinity™ s" Solution for Blood and Plasma Screening
finance.yahoo.com - April 23 at 5:03 PM
Johnson & Johnson’s Revenues Continued to Rise in 1Q18Johnson & Johnson’s Revenues Continued to Rise in 1Q18
finance.yahoo.com - April 23 at 5:03 PM
The Zacks Analyst Blog Highlights: Goldman, Abbott, Altria, PayPal and ProgressiveThe Zacks Analyst Blog Highlights: Goldman, Abbott, Altria, PayPal and Progressive
finance.yahoo.com - April 23 at 9:00 AM
FY2021 Earnings Forecast for Abbott Laboratories (ABT) Issued By GabelliFY2021 Earnings Forecast for Abbott Laboratories (ABT) Issued By Gabelli
www.americanbankingnews.com - April 23 at 3:04 AM
Abbott Laboratories (ABT) to Post Q2 2018 Earnings of $0.71 Per Share, Jefferies Group ForecastsAbbott Laboratories (ABT) to Post Q2 2018 Earnings of $0.71 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - April 23 at 1:54 AM
Abbott Laboratories (ABT) Forecasted to Earn Q2 2018 Earnings of $0.71 Per ShareAbbott Laboratories (ABT) Forecasted to Earn Q2 2018 Earnings of $0.71 Per Share
www.americanbankingnews.com - April 23 at 1:54 AM
William Blair Weighs in on Abbott Laboratories Q2 2018 Earnings (ABT)William Blair Weighs in on Abbott Laboratories' Q2 2018 Earnings (ABT)
www.americanbankingnews.com - April 23 at 1:54 AM
Abbott Laboratories (ABT) Rating Reiterated by BTIG ResearchAbbott Laboratories (ABT) Rating Reiterated by BTIG Research
www.americanbankingnews.com - April 22 at 8:16 AM
Abbott Laboratories (ABT) Coverage Initiated by Analysts at BTIG ResearchAbbott Laboratories (ABT) Coverage Initiated by Analysts at BTIG Research
www.americanbankingnews.com - April 20 at 6:24 PM
Top Analyst Reports for Goldman Sachs, Abbott & AltriaTop Analyst Reports for Goldman Sachs, Abbott & Altria
finance.yahoo.com - April 20 at 5:20 PM
Abbott Extends Title Sponsorship of Abbott World Marathon Majors through 2023Abbott Extends Title Sponsorship of Abbott World Marathon Majors through 2023
finance.yahoo.com - April 20 at 5:20 PM
Abbott Laboratories (ABT) Lifted to Buy at Zacks Investment ResearchAbbott Laboratories (ABT) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - April 20 at 11:54 AM
Earnings Reaction History: Abbott Laboratories, 63.6% Follow-Through Indicator, 2.4% SensitiveEarnings Reaction History: Abbott Laboratories, 63.6% Follow-Through Indicator, 2.4% Sensitive
www.nasdaq.com - April 20 at 8:33 AM
FY2018 EPS Estimates for Abbott Laboratories Increased by William Blair (ABT)FY2018 EPS Estimates for Abbott Laboratories Increased by William Blair (ABT)
www.americanbankingnews.com - April 20 at 8:32 AM
Abbott Laboratories (ABT) to Post Q3 2018 Earnings of $0.73 Per Share, Leerink Swann ForecastsAbbott Laboratories (ABT) to Post Q3 2018 Earnings of $0.73 Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - April 20 at 8:08 AM
Jefferies Group Weighs in on Abbott Laboratories Q3 2018 Earnings (ABT)Jefferies Group Weighs in on Abbott Laboratories' Q3 2018 Earnings (ABT)
www.americanbankingnews.com - April 20 at 8:08 AM
Abbott Laboratories (ABT) Earns Hold Rating from BMO Capital MarketsAbbott Laboratories (ABT) Earns Hold Rating from BMO Capital Markets
www.americanbankingnews.com - April 19 at 5:50 PM
Aortic Stenosis, And The Race To Catch Edwards Lifesciences' Heart ValvesAortic Stenosis, And The Race To Catch Edwards Lifesciences' Heart Valves
finance.yahoo.com - April 19 at 5:32 PM

SEC Filings

Abbott Laboratories (NYSE:ABT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Abbott Laboratories (NYSE:ABT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Abbott Laboratories (NYSE ABT) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.